Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment

A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains

(2020) Judith Everts‐Graber et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports

(2019) O. Lamy et al.   OSTEOPOROSIS INTERNATIONAL

Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature

(2019) Helena Florez et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical Trial

(2019) Athanasios D. Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study

(2019) Nobukazu Okimoto et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis

(2018) Albrecht Werner Popp et al.   CALCIFIED TISSUE INTERNATIONAL

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates

(2018) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

(2018) Stuart L. Silverman et al.   Archives of Osteoporosis

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

(2017) Athanasios D Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis

(2017) R. Niimi et al.   OSTEOPOROSIS INTERNATIONAL

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States

(2017) Emily Durden et al.   Archives of Osteoporosis

Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis

(2016) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study

(2014) A. Sakai et al.   OSTEOPOROSIS INTERNATIONAL

Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German database

(2012) Volker Ziller et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg

(2011) J. D. Wark et al.   OSTEOPOROSIS INTERNATIONAL

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

Vertebral fracture assessment using a semiquantitative technique

(2010) Harry K. Genant et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid

(2010) S. L. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases

(2008) Pierre D. Delmas   JOURNAL OF CLINICAL DENSITOMETRY